中文摘要：

目的探讨CYP3A5、MDR1和COX-2单核苷酸多态性是否与长春瑞滨、铂类药物对晚期非小细胞肺癌（NSCLC）化疔疗效有关。方法对69例采用长春瑞滨、铂类方案化疗的晚期NSCLC患者（中国汉族）的CYP3A5（＊3）、MDR1 21外显子上的2677 G〉T位点、26外显子3435 C〉T位点及其单体型和COX-2启动子区的-1195 G〉A位点用限制内切酶片段多态性一多聚酶链反应（RFLP—PCR）的方法进行基因分型，结合临床化疗效果进行分析，采用卡方检验分析各位点基因型与化疗疗效之间的关系。结果MDR1 3435位点野生纯合子（C／C）患者疗效明显高于杂合子（C／T）和突变纯合子（T／T）患者（P=0．033）。MDR12677位点野生纯合子（G／G）患者疗效明显高于其他基因型患者（P=0．012）。MDR1 2677 G-3435 C单体型患者疗效稍高于其他单体型（P=0．063）。CYP3A5＊3位点基因型与长春瑞滨、铂类方案疗效无关。COX-2-1195 G〉A位点野生型（G／G）疗效稍高于其他基因型（P=0.067），但差异无统计学意义。结论MDR13435 C〉T位点基因型和MDR1 2677 G〉A／T位点基因型可以用于预测长春瑞滨、铂类方案对晚期NSCLC患者的疗效。

英文摘要：

Objective To investigate whether genotypes of CYP3A5, MDR1 and cyclooxygenase-2 are associated with the sensitivity of vinorelbineplatinum to NSCLC. Methods The genotypes of CYP3 A5 （ ＊ 3 ） , MDRI （2677G 〉 T at exon 21 and 3435C 〉 T at exon 26 and their haplotypes）, cyclooxygenase-2 （ -1195 G 〉 A） were determined by RFLP-PCR and chemotherapy responses were analyzed in 69 non-small-cell lung cancer （NSCLC） Chinese Han patients. They received a combination chemotherapy of vinorelbine-cisplatin. Chi-square test was used to investigate the potential association of genotype with chemotherapy response. OR and 95% CI were calculated. Results The 3435 CC genotype was associated with a significantly better chemotherapy response compared with the combined 3435 CT and TT genotypes （ P = 0. 033 ）. The 2677 GG genotype was also associated with a significantly better chemotherapy response compared with the combined 2677 GT and TT genotype（P = 0. 012）. Moreover, patients with the 2677 G-3435 C haplotype seemed to have a better response to chemotherapy compared with those with the other haplotypes （ P = 0. 063 ）. CYP3A5 ＊ 3 was not likely to correlate with sensitivity of vinorelbine-platinum to NSCLC. Cyclooxygenase-2-1195G 〉 A was likely to have better response to vinorelbine but not statistically significant （P = 0. 067 ）. Conclusion Polymorphisms of MDR1 3435C 〉 T and MDR1 2677G 〉 A/T can be used for predicting treatment response to vinorel-bine-cisplatin chemotherapy in NSCLC patients.